|
1 Indications And Usage Tagrisso Is A Kinase Inhibitor Indicated For • The First-Line Treatment Of Patients With Metastatic Nsclc Whose Tumors Have Epidermal Growth Factor Receptor (Egfr) Exon 19 Deletions Or Exon 21 L858r Mutations, As Detected By An Fda-Approved Test. ( 1.1 , 2.1 ) • The Treatment Of Patients With Metastatic Egfr T790m Mutation-Positive Nsclc, As Detected By An Fda-Approved Test, Whose Disease Has Progressed On Or After Egfr Tki Therapy. ( 1.2 , 2.1 ) 1.1 First-Line Treatment Of Egfr Mutation-Positive Metastatic Non-Small Cell Lung Cancer (Nsclc) Tagrisso Is Indicated For The First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (Nsclc) Whose Tumors Have Epidermal Growth Factor Receptor (Egfr) Exon 19 Deletions Or Exon 21 L858r Mutations, As Detected By An Fda-Approved Test [See Dosage And Administration (2.1) ] . 1.2 Previously Treated Egfr T790m Mutation-Positive Metastatic Nsclc Tagrisso Is Indicated For The Treatment Of Patients With Metastatic Egfr T790m Mutation-Positive Nsclc, As Detected By An Fda-Approved Test, Whose Disease Has Progressed On Or After Egfr Tyrosine Kinase Inhibitor (Tki) Therapy [See Dosage And Administration (2.1) ] .
|